Singapore: BioTime, a regenerative biotechnology company, has appointed Dr Lesley Stolz, as executive vice president, corporate development.

"Lesley brings a strong background in corporate and business development to BioTime including more than twenty successfully concluded technology and therapeutics partnering and financing transactions in the life sciences," said Dr Michael D West, CEO, BioTime.

"She will have primary responsibility for interactions with both investors and corporate partners. Additionally, she will focus on identifying and implementing strategic initiatives for BioTime and its subsidiaries. Lesley will work with corporate partners and investors on the next stage of BioTime's development. It is likely that many regenerative medicine therapeutics will be developed through partnerships between biotechnology companies and commercial therapeutics companies," Dr West added.